Navigation Links
Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer

NEW HAVEN, Conn., June 04, 2007 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. announced that it presented updated clinical data in a poster session at the 43rd Annual Meeting of The American Society of Clinical Oncology (ASCO) on its lead anticancer agent Cloretazine(R) (VNP40101M) as a single agent in a Phase II trial in patients with relapsed or refractory small cell lung cancer.

The Phase II trial evaluates Cloretazine(R) (VNP40101M) in two separate subpopulations of small cell lung cancer: (i) sensitive relapse disease and (ii) refractory disease. Sensitive relapse disease is defined as relapse after three months of first-line therapy and refractory disease is defined as relapse within three months of first-line therapy. Data are presented on a total of 48 evaluable patients: (i) 20 patients in the sensitive relapse arm and (ii) 28 patients in the refractory arm.

Patients on the trial initially received 125 mg/m2 of Cloretazine(R) (VNP40101M) weekly for three weeks, every six weeks. This dose was later reduced by protocol amendment to 100 mg/m2 weekly for three weeks every six weeks due to the incidence of grade 3 and 4 thrombocytopenia at the initial dose level.

Of the 20 evaluable patients on the sensitive relapse arm, there have been 6 patients with partial response and one patient awaiting confirmation of response (overall, 35% response rate), and 3 patients have stable disease. Four of 13 sensitive relapse patients responded at the 125 mg/m2 dose level and 3 of 7 sensitive relapse patients responded at the 100 mg/m2 dose level. Of the 28 patients with refractory disease treated with Cloretazine(R) (VNP40101M), 1 patient achieved a partial response and 3 patients have demonstrated stable disease.

A total of 55 patients were evaluable for toxicity. Grade 3 and 4 thrombocytopenia was observed in 14 of 31 patients (45%) at the 125 mg/m2 dose level. Thrombocytopenia was su
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
(Date:7/10/2014)... July 10, 2014 CVS Caremark Corporation (NYSE: ... has approved a quarterly dividend of $0.275 (27.5 cents) per ... on August 1, 2014, to holders of record on July ... CVS Caremark is dedicated to helping people on their path ... the United States . Through the company,s ...
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... 26, 2011 Vapotherm announced today the launch ... specifically for homecare and other low acuity environments. ... and European markets. Vapotherm,s Flowrest® ... home and other extended care environments.  According to ...
... 26, 2011 Omnicell, Inc . (NASDAQ: ... medication and supply management solutions and analytics software ... Victoria Hospital (RVH) selected Omnicell G4 solutions ... by Omnicell,s hallmark flexibility and functionality, RVH became ...
Cached Medicine Technology:Vapotherm Announces Commercial Launch of Flowrest® Homecare Device 2Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 2Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 3Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 4
(Date:7/13/2014)... New York (PRWEB) July 13, 2014 ... bring attention to the cancer risks associated with power ... to tell their story to federal regulators, as they ... U.S. Food & Drug Administration (FDA) advisory panel ... reports. According to the Rochester Democrat and Chronicle, ...
(Date:7/13/2014)... July 13, 2014 Recently, 2014QuinceaneraDresses.com, ... has unveiled its new range of gorgeous ... market, the demand for elegant Quinceanera outfits is ... beautiful items. All the company’s newly released dresses ... They are all elegant and vivid. , ...
(Date:7/13/2014)... ANGELES A noninvasive optical imaging device developed ... that later occur in the brain and are ... preliminary results from investigators conducting a clinical trial ... findings July 15 in an oral presentation at ... Denmark. They also were invited by conference organizers ...
(Date:7/13/2014)... California (PRWEB) July 13, 2014 Celebrity ... Musico has formed a promotional partnership with Aqua Health ... based Omega-3 EPA supplement . The collaboration was ... a celebrity fitness trainer , actor, model, and ... go-to trainer for A-List celebrities, he has prepared stars ...
(Date:7/13/2014)... July 13, 2014 According to the ... this is a comprehensive guide that features a series ... with KP (keratosis pilaris). This guide consists of ... Is Keratosis Pilaris? ,     Chapter 2: What Cause ... If I Have KP? ,     Chapter 4: Keratosis ...
Breaking Medicine News(10 mins):Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3
... WASHINGTON, March 28 Thousands of epilepsy advocates, caregivers, ... celebrities at the nation,s Capitol today to support the ... two years, the event has raised more than $2 ... event is expected to increase those numbers significantly. Money ...
... could replace anti-clotting drug warfarin for many patients, researchers ... implanted device may soon replace the anti-clotting drug warfarin ... with atrial fibrillation, a new study suggests. , People ... stroke, the researchers noted, and typically need to take ...
... in era of rising costs , , FRIDAY, March 27 (HealthDay ... national health care reform when she was first lady in ... are working -- are without health insurance. , That finding ... a state-by-state picture of people foregoing insurance because of rising ...
... Drug-eluting stents were safe and superior to bare metal ... "real-world" patients enrolled in a nationwide registry of cardiovascular ... , The findings were presented today at the ... Scientific Session. They also appear online in the ...
... (NYSE: NUS ) announced that more than 100,000 ... the company,s distributors and customers who have purchased Epoch Baobab ... company has donated $0.25 from the sale of every Epoch ... Foundation,s Seeds of Hope reforestation project. "When someone purchases a ...
... Earnings Guidance to a Minimum of $0.25 per diluted ... Service Corporation (Nasdaq: PRSC ) today announced ... December 31, 2008. Included in the results is ... related to the Company,s intangible assets, which, when added ...
Cached Medicine News:Health News:Video: Celebrities and Thousands of Walkers Unite at Nation's Capitol to Raise Awareness About Seizures and Epilepsy 2Health News:Video: Celebrities and Thousands of Walkers Unite at Nation's Capitol to Raise Awareness About Seizures and Epilepsy 3Health News:New Device Treats Common Heart Rhythm Disorder 2Health News:New Device Treats Common Heart Rhythm Disorder 3Health News:One in Five Working Adults Said to Lack Health Insurance 2Health News:Drug-eluting stents found safe, superior to bare metal stents 2Health News:Nu Skin Charitable Promotion Reaches Important Milestone: 100,000 Trees Donated to African Nation of Malawi 2Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 2Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 3Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 4Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 5Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 6Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 7Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 8Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 9Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 10Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 11Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 12Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 13Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 14
... Maximum Xtra, and Maximum ACT introducers ... and specialty hemostasis introducers in the ... premier hemostasis introducers for use in ... angiography, angioplasty, stenting, atherectomy, temporary pacing, ...
St. Jude Medical's line of guiding introducers includes Swartz Series, SAFL, SEPT, CSTA, RAMP, and 2 piece steerable...
The intended use of the percutaneous PREFACE Guiding Sheath is for the introduction of intravascular electrophysiology catheters into any cardiac chamber....
... EP Systems sells the popular transeptal ... needles. These products allow left atrial ... catheter ablation of left-sided arrhythmogenic substrates. ... others use it when a transaortic ...
Medicine Products: